ICI-85966
ICI-85966 is a drug that was developed by Imperial Chemical Industries (ICI) and is known for its analgesic properties. It is a kappa opioid receptor agonist, which means it binds to and activates the kappa opioid receptors in the brain and spinal cord, leading to pain relief.
History[edit | edit source]
ICI-85966 was developed by the British company Imperial Chemical Industries in the late 20th century. The company, now known as AstraZeneca, has a long history of developing innovative drugs for a variety of medical conditions.
Mechanism of Action[edit | edit source]
As a kappa opioid receptor agonist, ICI-85966 works by binding to and activating the kappa opioid receptors in the brain and spinal cord. This activation inhibits the release of substance P, a neurotransmitter involved in pain transmission, thereby reducing the perception of pain.
Clinical Use[edit | edit source]
While ICI-85966 has demonstrated analgesic properties, its use in clinical practice is limited due to its potential for causing dysphoria, a state of unease or dissatisfaction. This is a common side effect of kappa opioid receptor agonists.
Side Effects[edit | edit source]
The most common side effect of ICI-85966 is dysphoria. Other potential side effects include sedation, nausea, and vomiting. These side effects are generally dose-dependent and may be more pronounced in individuals who are opioid-naive.
See Also[edit | edit source]
ICI-85966 Resources | ||
---|---|---|
|
|
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD